Clinical Evaluation of 5 Days of Administration of 6-Mercaptopurine at the Dose of 175 mg/m2/day Versus 250 mg/m2/day

• Published in: The Japanese Journal of Pediatric Hematology Vol. 15; no. 5; pp. 367 - 371
• Main Authors: FUJIMOTO, Takeo, HIROTA, Takahisa, IWATA, Atsuko, MATSUSHITA, Takeji, HORI, Toshinori
• Format: Journal Article
• Language: Japanese
• Published: THE JAPANESE SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY 2001; 特定非営利活動法人 日本小児血液・がん学会
• Subjects: 6-mercaptopurine; acute lymphoblastic leukemia; children; side effect; tolerated dose
• ISSN: 0913-8706; 1884-4723
• DOI: 10.11412/jjph1987.15.367

Oral 6-mercaptopurine (6-MP) is an integral component of maintenance chemotherapy for children with acute lymphoblastic leukemia (ALL). A clinical comparative study of 6-MP given at 175 mg/m2/day vs. 250 mg/m2/day for 5 days was carried out. Ten patients on a CCLSG ALL 874 and 911 study received 6-MP at 175 mg/m2/day and 9 patients on a CCLSG ALL 941 study received 6-MP at 250 mg/m2/day. There was no significant difference in the value of WBC, Hb, and platelet counts between these two groups. The mean value of GPT level was significantly increased in a higher dosage group with no delay of 6-MP administration. The mean value of GPT peak level was decreased gradually following repeated cycles of 6-MP administration. Five days of 6-MP at 250 mg/m2/day was well tolerated and safe for the maintenance chemotherapy of childhood ALL.